AzTrials
AzTrials

Peripheral T Cell LymphomaPhase 2/3NCT06548347

A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma

A Phase 2/3 study testing Linperlisib in people with Peripheral T Cell Lymphoma, run by Shanghai YingLi Pharmaceutical Co. Ltd..

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Official record
Search all trials

Trial summary

This is a Phase II/III, international multiple center study to evaluate the efficacy, safety, and PK of Linperlisib plus CHOP and CHOP in adult patients with Newly Diagnosed Peripheral T Cell Lymphoma. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Peripheral T Cell Lymphoma
What is being tested?
Linperlisib
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
606 participants
Where
No sites listed yet
Study dates
10 Sep 2024to 30 Sep 2029
Phase
Phase 2/3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 1. Adult patient 18-70 years of age at the time of signing the informed consent.
  • 2. Diagnosis of one of the following histologic subtypes of PTCL, pathologically confirmed, as defined by the WHO 2017 classification system:
  • Peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS)
  • Angioimmunoblastic T-cell lymphomas (AITL)
  • Anaplastic large cell lymphoma (ALCL). ALK positive or ALK negative
  • Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL).
Show all 13Show fewer
  • Follicular T-cell Lymphoma (FTCL). 3. Newly diagnosed and has no received systemic therapy for PTCL. 4. Has a life expectancy ≥6 months. 5. For patients with CD30+ PTCL, progressed on or are ineligible or intolerant to brentuximab vedotin, or progressed on or are ineligible or intolerant to regional standard of care if brentuximab vedotin not approved or not available.
  • 6. Agree to provide archival tumor tissue samples or undergo pretreatment fresh tissue biopsy.
  • 7. Has radiographically measurable disease of PTCL as per Lugano Criteria with at least one measurable disease lesion > 1.5 cm in at least one dimension (which has not been previous radiated) by 18FDG-PET-CT, MRI, or diagnostic CT within 28 days prior to start of study treatment.
  • 8. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
  • 9. Has adequate organ function as defined below: System Laboratory Value Haematological Absolute neutrophil count ≥1.5×109/L Note: No growth factor supports within 14 days of first dose Platelet count ≥75×109/L Note: No blood product transfusion is allowed within 14 days of first dose Haemoglobin ≥80 g/L Note: criteria must be met without erythropoietin dependency and no blood product transfusion is allowed within 14 days of first dose Hepatic Total bilirubin ≤1.5×ULN Note: Patients with Gilbert's Syndrome or other benign congenital hyperbilirubinemia may be eligible at the Investigator's discretion in consultation with the Medical Monitor, if ≤ 3 × ULN Alanine aminotransferase ≤2.5×ULN Note: ≤ 5 × ULN if there is liver involvement by lymphoma Aspartate aminotransferase ≤2.5×ULN Note: ≤ 5 × ULN if there is liver involvement by lymphoma Renal CrCl calculated by Cockcroft-Gault formula CrCl ≥50 mL/min or SCr≤1.5×ULN Cardiac Left ventricular ejection fraction LVEF ≥ 50% by an echocardiogram (ECHO) or multigated acquisition scan (MUGA).
  • QTcF <450 ms Abbreviations: CrCl=creatinine clearance; RBC=red blood cell; QTcF=QT interval corrected using Fridericia's formula; ULN=upper limit of normal.
  • 10. Male patients are eligible to participate if they agree to use a highly effective contraception during the treatment period and for at least 6 months after the last dose of study treatment and refrain from donating sperm during this period 11. Female patients are eligible to participate if they are not pregnant, not breastfeeding, and at least one of the following conditions applies: 12. Patient must be willing and able to adhere to the study and are capable of giving signed informed consent.

Who cannot join

  • Patients are excluded from the study if any of the following criteria apply:
  • Has received anti-lymphoma therapy.
  • Patients with extranodal NK/T-cell lymphoma or CTCL.
  • Has dropsy of serous cavity not under controlled by surgical drains or other therapy.
  • Patients with peripheral T-cell lymphoma having known central nervous system (CNS) invasion (either CNS lymphoma or leptomeningeal lymphoma).
  • Has received systemic steroids (in dosing exceeding 20 mg daily of prednisone equivalent) within 14 days of the first dose of study treatment.
Show all 25Show fewer
  • Presence of multiple factors affecting drug administration and absorption such as inability to swallow, diarrhea of CTCAE Grade >1, and ileus. Use of any drug that may result in QT prolongation (e.g., antiarrhythmic agents) cannot be interrupted during the study.
  • Has a history of or concurrent interstitial lung disease of any severity and/or severely impaired lung function.
  • Has active viral, bacterial, fungal infection or other serious infection requiring systemic treatment within 14 days before the first dose of study treatment. Routine antimicrobial prophylaxis is permitted.
  • Has received a live vaccination within 30 days before the first dose of study treatment or is scheduled to be administered during the study period. Examples of live vaccines include but are not limited to the following: measles, mumps, rubella, varicella/zoster, yellow fever, Bacille Calmette-Guérin (BCG) and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.
  • Medical history of other primary malignant tumors in the past 5 years, or any evidence of residual disease from a previously diagnosed malignancy.
  • Note: Exceptions are patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (e.g., breast, cervical cancer in situ, superficial bladder tumors [Ta and Tis; carcinoma in situ]) who have undergone curative therapy with no evidence of recurrence, localized prostate cancer previously fully resected undergoing surveillance or other adequately treated Stage 1 cancer currently in complete remission.
  • Uncontrolled pulmonary fibrosis, acute lung disease, interstitial lung disease, etc;
  • Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication, any other cardiac disorder not suitable for participation in this study based on the judgment of the investigator.
  • Note: During the treatment period, patients should not take medication that may prolong the QT (such as antiarrhythmic drugs).
  • Decompensated cirrhosis (Child-Pugh: B or C). Patients with active viral (any etiology) hepatitis (HbsAg and/or HbcAb positive and HBV-DNA positive) are excluded. Patients with a history of hepatitis C virus (HCV) infection (Hepatitis C antibody positive and HCV-RNA positive).
  • Medical history of immunodeficiency syndrome (AIDS)-defining illness, including Human immunodeficiency virus (HIV) infection, or allogeneic bone marrow/stem cells transplant or organ transplant, or has active autoimmune diseases or has medical history of autoimmune diseases (such as autoimmune enteritis, systemic lupus erythematosus);
  • Has undergone major surgery (excluding lymph node biopsy) or significant trauma ≤4 weeks before the first dose of study treatment.
  • Note: patients must have recovered adequately from surgery prior to starting study treatment.
  • Has a history or current evidence of any condition, laboratory abnormality or other circumstances that might confound the results of the study or interfere with participation for the full duration of the study, such that it is not in the best interests of the patient to take part in the study.
  • Medical history of active bleeding within 2 months prior to study entry, or susceptible to bleeding by the judgement of investigator.
  • Has a history of hypersensitivity to Linperlisib and CHOP and/or any excipients.
  • Female patient are pregnant, and are breastfeeding.
  • Has had received prior systemic cytotoxic anticancer therapy, or definitive radiotherapy within 28 days prior to the first dose of study treatment.
  • Judgment by the investigator that the volunteer should not participate in the study.

About this study

Official title: A International Multicenter, Randomized, Double-Blind, Controlled Phase II/III Study to Evaluate the Efficacy and Safety of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma

This is a Phase II/III, international multiple center study to evaluate the efficacy, safety, and PK of Linperlisib plus CHOP and CHOP in adult patients with Newly Diagnosed Peripheral T Cell Lymphoma.

Being tested
Linperlisib
Medical subject headings
Lymphoma, T-Cell, Peripheral

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LinperlisibDrug

    Also called CHOP

    Linperlisib at 80 mg orally once daily (QD) or 60mg orally once daily (QD) plus CHOP, placebo at 80mg or 60 mg orally once daily (QD) plus CHOP for 6 cycles

Study groups in NCT06548347
Study groupRoleWhat they receive
Linperlisib80mg+CHOPExperimentalNot described
Receives: Drug: Linperlisib
Linperlisib60mg+CHOPExperimentalNot described
Receives: Drug: Linperlisib
CHOPActive comparatorNot described
Receives: Drug: Linperlisib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall response rate

    Measured: Study treatment will continue until unacceptable toxicity or documented disease progression, or for 2 years, whichever is earlier.

  2. progression-free survival

    Measured: Study treatment will continue until unacceptable toxicity or documented disease progression, or for 2 years, whichever is earlier.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Aug 2024
  2. Study start10 Sep 2024 (estimated)
  3. Primary completion31 Dec 2024 (estimated)
  4. Study completion30 Sep 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
606 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06548347
Sponsor's protocol ID
YY-20394-015
Status last verified
Aug 2024
First submitted
7 Aug 2024
Last updated
12 Aug 2024
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing Linperlisib in people with Peripheral T Cell Lymphoma, run by Shanghai YingLi Pharmaceutical Co. Ltd..

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 12 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall response rate (time frame: Study treatment will continue until unacceptable toxicity or documented disease progression, or for 2 years, whichever is earlier.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06548347.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in